PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit, your source for the latest clinical literature updates. Today, we’re discussing a phase 3b trial on tildrakizumab for moderate-to-severe scalp psoriasis, with week 52 results. Seth, scalp psoriasis is notoriously challenging, isn’t it?
Seth: Absolutely, Britany. Up to 80% of psoriasis patients have scalp involvement, which impacts quality of life due to visibility, itching, and scaling. Many systemic therapies don’t specifically target the scalp well or have tolerability issues.
Britany: Right, and despite advances, scalp-specific long-term data remain scarce. The ReSURFACE 1 and 2 trials showed tildrakizumab’s efficacy in plaque psoriasis but didn’t focus on scalp outcomes. This study fills that gap.
Seth: Exactly. This trial evaluated tildrakizumab, an IL-23 p19 monoclonal antibody, using scalp-specific endpoints like the Investigator Global Assessment modified 2011 and Psoriasis Scalp Severity Index (PSSI) over a year. That’s crucial for understanding sustained efficacy and safety in this tough area.
Britany: The rationale is clear: to support long-term management and maintenance dosing for scalp psoriasis, which is challenging due to hair density and unique skin affecting drug response.
Seth: Plus, patients often struggle with adherence due to visibility and discomfort. A well-tolerated systemic option with infrequent dosing like tildrakizumab every 12 weeks could be a game-changer.
Britany: The study was a phase 3b, randomized, double-blind, placebo-controlled trial with a crossover design, minimizing bias and allowing placebo patients to receive active treatment after week 16.
Seth: Adults with moderate-to-severe scalp psoriasis, defined by IGA modified 2011 score ≥3 and significant baseline PSSI, were included. Patients with prior biologic failure, recent systemic therapy, or contraindicating comorbidities were excluded.
Britany: Excluding recent systemic therapy and biologic failures focused the study on a relatively treatment-naïve or biologic-responsive population, which may affect generalizability but clarifies efficacy signals.
Seth: The intervention was tildrakizumab 100 mg subcutaneously every 12 weeks, consistent with approved dosing. Placebo patients crossed over to tildrakizumab at week 16, allowing assessment of delayed treatment effects.
Britany: The primary endpoint was the proportion achieving an IGA scalp score of 0 or 1 with at least a 2-grade improvement. Secondary endpoints included ≥90% improvement in PSSI. Safety was assessed by treatment-emergent and serious adverse events.
Seth: Analysis was intention-to-treat, with chi-square or Fisher’s exact tests for response comparisons. Subgroup analyses by baseline severity and prior treatment added depth.
Britany: Patient demographics were balanced, mean age 45–50 years, with slight male predominance, consistent with psoriasis epidemiology.
Seth: Disease characteristics confirmed moderate-to-severe scalp involvement by IGA and PSSI, ensuring clinical relevance.
Britany: Regarding efficacy, tildrakizumab patients’ IGA response improved from 49.4% at week 16 to 62.9% at week 52, showing sustained and enhanced efficacy.
Seth: Similarly, ≥90% PSSI improvement rose from 60.7% to 65.2% over the same period, indicating durable scalp clearance.
Britany: Placebo patients crossing over to tildrakizumab saw IGA response jump from 7.3% to 56.1%, and PSSI 90% improvement from 4.9% to 57.3% by week 52, confirming efficacy even when started later.
Seth: Over 80% of week 16 responders maintained response through week 52, highlighting durability—critical for chronic psoriasis.
Britany: Safety-wise, no treatment-related serious adverse events occurred. The safety profile matched previous tildrakizumab studies, supporting long-term tolerability.
Seth: That’s reassuring, especially since scalp psoriasis requires prolonged therapy. The 12-week dosing likely improves adherence and reduces injection site reactions.
Britany: For context, ReSURFACE 1 and 2 showed sustained efficacy and safety of tildrakizumab over 148 weeks in plaque psoriasis, with maintained PASI responses.
Seth: A phase 4 real-world study reported an 83.1% reduction in body surface area and 67.6% improvement in Physician Global Assessment over 64 weeks, with no new safety concerns, supporting these findings.
Britany: An Italian retrospective study showed PASI scores dropping from 14.19 to 1.76 at week 28, with PASI75 and PASI90 rates of 81.0% and 64.4%, reinforcing effectiveness.
Seth: The IL-23 p19 antibody class, including tildrakizumab, is emerging as highly effective for moderate-to-severe plaque psoriasis, including scalp involvement, with advantages over older biologics.
Britany: Mechanistically, tildrakizumab selectively inhibits IL-23’s p19 subunit, pivotal in the Th17 pathway driving psoriasis, reducing inflammation with fewer off-target effects.
Seth: By sparing IL-12, which shares the p40 subunit, tildrakizumab may preserve some immune functions, contributing to its favorable safety profile.
Britany: Monitoring is minimal but clinicians should watch for infections or hypersensitivity. Patient education on injection technique and adherence is important.
Seth: Drug interactions are limited since tildrakizumab is metabolized proteolytically, not via cytochrome P450 enzymes, simplifying management in polypharmacy.
Britany: Special populations like elderly or those with comorbidities were excluded here, but real-world data suggest good tolerability across groups. Individualized assessment remains essential.
Seth: For hepatic or renal impairment, no dose adjustments are recommended, but clinical judgment is prudent. The infrequent dosing benefits adherence.
Britany: In summary, this phase 3b trial provides robust evidence that tildrakizumab is a safe, effective long-term treatment for moderate-to-severe scalp psoriasis, with durable responses and convenient dosing.
Seth: It fills a key gap by focusing on scalp-specific endpoints, showing targeted IL-23 inhibition achieves meaningful improvements in this difficult area.
Britany: For clinicians, recognizing tildrakizumab’s role can enhance counseling, optimize adherence, and improve quality of life for patients with scalp psoriasis.
Seth: Ongoing vigilance for adverse events and patient factors will ensure safe, effective use. This study adds to our tools for managing scalp psoriasis.
Britany: Thanks for the discussion, Seth. And thank you to our listeners for tuning in to PACULit. Stay current, stay curious, and we’ll catch you next time.
Seth: Looking forward to it, Britany. Take care everyone!